Kim joined Polaris in 2023 and is a principal in the Singapore research office.
Prior to joining Polaris, Kim was Vice President at Temasek’s Healthcare Investment team, with a focus on biopharma and early stage investments. Before that, she performed her postdoctoral research under the guidance of Dr. Sydney Brenner.
Kim received her PhD from Rockefeller University, where she studied cancer biology and drug discovery. She holds an MBA from Singapore Management University and a BSE in Biomedical Engineering from Duke University.